Send to

Choose Destination
Expert Rev Anti Infect Ther. 2008 Dec;6(6):797-803. doi: 10.1586/14787210.6.6.797.

Tipranavir: a new protease inhibitor for the pediatric population.

Author information

University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, CT, USA.


Highly active antiretroviral therapy can provide sustained viral suppression and a beneficial immunological response in both antiretroviral-naive and -experienced pediatric patients infected with HIV. While there have been many antiretroviral studies in adults infected with HIV, considerably less information is available in similar HIV-infected pediatric or adolescent patients. Tipranavir, a new-generation protease inhibitor approved for use in adults with resistant HIV strains, has recently been studied in HIV-infected children and adolescents. In this article, we summarize available pharmacokinetic, safety, tolerability and efficacy data obtained from children and adolescents treated with a pediatric tipranavir formulation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center